Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
Online ISSN : 1882-8272
Print ISSN : 0388-1601
ISSN-L : 0388-1601
Search
Advanced search
OR
Browse
Search
Volume 39, Issue 2
Displaying 1-14 of 14 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Feature Articles : New projects for clinical trials in Japan
ORIGINAL
  • Clinical Pharmacological Study to Evaluate the Drug Interaction between Histamine H1 Receptor Antagonist Ebastine and Verapamil, P-gp Inhibitor at the Blood Brain Barrier: Objective Evaluation Using Saccadic Eye Movement Analysis
    Dai SAKUMA, Naoki UCHIDA, Mariko IWASE, Yusuke SAITO, Masaki MOCHII, K ...
    2008 Volume 39 Issue 2 Pages 71-78
    Published: 2008
    Released on J-STAGE: November 06, 2008
    DOIhttps://doi.org/10.3999/jscpt.39.71
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    First-generation antihistamines have an adverse CNS effect such as sedation, whereas second-generation antihistamine drugs are generally non-sedating. The difference in the CNS sedation profile is mainly due to the CNS penetration of the drugs. We hypothesized that the non-sedating profile is caused by low CNS penetration due to regulation by the P-glycoprotein (P-gp) efflux transporter at the blood brain barrier (BBB). A three-way crossover study with more than a 6-day washout period was performed in 8 healthy volunteers. In order to evaluate the drug interaction on P-gp, we used ebastin (Eb) from the second-generation antihistamines and verapamil (Vr) as an inhibitor of P-gp. The three study medication groups were as follows: a single oral dose of Eb 10 mg (E10); a single oral dose of Eb 20 mg (E20); and a single oral dose of Eb 10 mg together with a single oral dose of Vr 80 mg at 3 hours after Eb dosing (EV). The sedative side effect of Eb was measured by both saccadic peak velocity (SPV) analysis, as an objective evaluation, and the visual analogue self-rating scale (VAS), as a subjective evaluation. No sedative effect was observed in any group. These results suggest that Eb has no clinically significant sedative effect even when the Eb dose is increased or with co-administration of P-gp inhibitor.
    View full abstract
    Download PDF (349K)
Proceedings of the 28th annual meeting of Japanese Society of Clinical Pharmacology and Therapeutics
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top